ProQR Therapeutics NV expected to post a loss of 8 cents a share - Earnings Preview

• ProQR Therapeutics NV PRQR is expected to show a fall in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025

• The Leiden Zuid-holland-based company is expected to report a 29.4% decrease in revenue to €4.452 million from €6.31 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 8 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 76.7% above its last closing price of $2.10

Previous quarterly performance (using preferred earnings measure in euros). ​

This summary was machine generated August 1 at 13:31 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)